Christopher G. Clement
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sim Fass | M | 82 | 21 years | |
| David Gionco | M | 63 | - | |
| Paul R. Hamelin | M | 69 | 5 years | |
| Philip K. Yachmetz | M | 67 | 10 years | |
| Stephen Jaeger | M | 79 | - | |
| Brian J. Hayden | M | 72 | 3 years | |
| Robert M. Shaw | M | 70 | 6 years | |
| Whitney K. Stearns | M | - | 1 years | |
| David L. Fink | M | - | - | |
| Zebulun D. Horowitz | M | 72 | 6 years | |
| Donald A. Fishbein | M | - | 2 years | |
| Neil M. Cowen | M | - |
Epicyte Pharmaceutical, Inc.
 Epicyte Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Epicyte Pharmaceutical, Inc. develops biopharmaceuticals. The American company was founded by Mich B. Hein. Epicyte Pharmaceutical was acquired by Biolex Therapeutics, Inc. on May 06, 2004. | 2 years |
| Lee S. Simon | M | 73 | - | |
| Alan L. Heller | M | 70 | - | |
| Clifford T. Bacsik | M | - | 1 years | |
| Mich B. Hein | M | - |
Epicyte Pharmaceutical, Inc.
Epicyte Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Epicyte Pharmaceutical, Inc. develops biopharmaceuticals. The American company was founded by Mich B. Hein. Epicyte Pharmaceutical was acquired by Biolex Therapeutics, Inc. on May 06, 2004. | 5 years |
| Jeremy Hayward-Surry | M | 81 | - | |
| Norman W. Barton | M | - | 6 years | |
| Gina Gutzeit | F | 62 | - | |
| Robert Lamm | M | 69 | 7 years | |
| Lawrence A. Gyenes | M | 73 | 1 years | |
| Kathryn Cole | F | 59 | 5 years | |
| Yehuda Sternlicht | M | 69 | 11 years | |
| Gregory Wujek | M | 62 | 1 years | |
| Herbert Weissbach | M | - | - | |
| Carl E. Kaplan | M | - | - | |
| Ana I. Stancic | F | 66 | 1 years | |
| Joseph Klein | M | 62 | - | |
| Faye Wattleton | F | 80 | 10 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 29 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christopher G. Clement
- Personal Network
